Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Last Price: 8.04 - Change: 0.11 - Change %: 1.3871
Industry: Information Technology ServicesFollow @stockchartsai on Twitter
In the past 30 trading days, CLVT has been trading in a range between $7.44 and $6.26 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
CLVT is trading between resistance at $8.68 about 8% to the upside and support at $7.35 -9% to the downside. If it can break above the resistance, it could have some more upside to the next line of resistance at $9.90, about a 23% move. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
CLARIVATE PLC (CLVT) entered a Green zone 17 days ago on the AI powered stock chart. Wall Street analysts have a recent rating of 3.636, which is a Buy. The current analyst target price is $8.5, which gives it a potential upside of 5.72 % from the recent price of 8.04. The stock is trading 49.13% (potential upside) below its 52 week high of $11.99 and 32.45 % (potential downside) above its 52 week low of $6.07 - based on the recent price.
Clarivate Plc, an information, analytics, and workflow company, provides structured information and analytics for discovery, development, protection, commercialization, and measurement of scientific research, innovations, and brands The company operates through three segments: Academia and Government, Life Sciences and Healthcare, and Intellectual Property. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ProQuest One, Pivot, Polaris, eBook Central, Vegs, Alma, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis products for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs; and Real World Data, Dialog, Drug Safety Triager, and healthcare and data solutions.
|Clarivate Expands Partnership with VeriSIM Life to Accelerate and De-risk Research and Drug Development
New AI-enabled, integrated workflow provides pharma and biotech companies with comprehensive R&D insights to help minimize late-stage failures during clinical trials LONDON , Dec. 5, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the launch of VeriSIM Life Translational Index™ on Cortellis Drug Discovery Intelligence by Clarivate. The integrated workflow provides customers with a diverse array of predictive compound safety and efficacy insights, including bioavailability, hepatic and renal clearance, clinical toxicity, first-in-human dose and more.
Tue, 05 Dec 2023 02:00:00 -0500
|Clarivate Reveals World's Influential Researchers in Highly Cited Researchers 2023 List
Concentration of top talent with 10 countries/regions representing over 80% of list LONDON , Nov. 15, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today revealed its 2023 list of Highly Cited Researchers™ – influential researchers at universities, research institutes and commercial organizations around the world who have demonstrated significant and broad influence in their field(s) of research. Analysts at the Institute for Scientific Information (ISI)™ have recognized 6,849 Highly Cited Researchers in 2023, from more than 1,300 institutions in 67 nations and regions.
Wed, 15 Nov 2023 03:00:00 -0500
|Clarivate to Present at the RBC Capital Markets 2023 Technology, Internet, Media and Telecommunications Conference on November 14, 2023
LONDON , Nov. 8, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a global leader in connecting people and organizations to intelligence they can trust to transform their world, announced today that Jonathan Gear, Chief Executive Officer, will present at the RBC Capital Markets 2023 Technology, Internet, Media and Telecommunications Conference on Tuesday, November 14, 2023 at 1:20 pm Eastern Time. The live webcast can be accessed at https://www.veracast.com/webcasts/rbc/tmit2023/67C540.cfm and will be available for replay.
Wed, 08 Nov 2023 16:15:00 -0500
|Clarivate Plc (CLVT) Q3 2023 Earnings Call Transcript
Clarivate Plc (NYSE:CLVT ) Q3 2023 Earnings Conference Call November 7, 2023 9:00 AM ET Company Participants Mark Donohue - Vice President, Investor Relations Jonathan Gear - Chief Executive Officer Jonathan Collins - Executive Vice President and Chief Financial Officer Conference Call Participants Toni Kaplan - Morgan Stanley Manav Patnaik - Barclays Surinder Thind - Jefferies Andrew Nicholas - William Blair John Mazzoni - Wells Fargo Owen Lau - Oppenheimer Ashish Sabadra - RBC Capital Markets Peter Christiansen - Citi George Tong - Goldman Sachs Operator Good morning. Thank you for attending today's Clarivate Third Quarter 2023 Earnings Call.
Source: Seeking Alpha
Tue, 07 Nov 2023 13:57:09 -0500
|Compared to Estimates, Clarivate PLC (CLVT) Q3 Earnings: A Look at Key Metrics
The headline numbers for Clarivate PLC (CLVT) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Source: Zacks Investment Research
Tue, 07 Nov 2023 10:31:39 -0500
Stock Analyzed Each Night
Easily Upload Track Your Stocks
See Lists of Stocks Starting New Trends
The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.